Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Palbociclib (125mg) Capsule
Therapeutic Category
Oncology, Anticancer
Dosage Form
Capsule
Packaging Type
in a Bottle
Packaging
21 Capsules
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Palbocare Capsule (Palbociclib 125 mg) is a critical oral medication in modern oncology, belonging to the class of Cyclin-Dependent Kinase 4/6 (CDK 4/6) Inhibitors. It is the standard cornerstone treatment for patients with Hormone Receptor-Positive (HR+), HER2-Negative advanced or metastatic breast cancer.
Mechanism and Impact:Palbociclib works by selectively and reversibly inhibiting CDK 4 and CDK 6 proteins. This action arrests the cancer cells in the G1 phase of the cell cycle, preventing uncontrolled proliferation. When used in combination with endocrine therapy, it significantly delays disease progression and extends life.
We offer an exclusive PCD Pharma Franchise opportunity for Palbocare Capsule, enabling partners to dominate the premium oral targeted oncology segment.
Hair loss (alopecia) Nausea, vomiting, diarrhea Low blood counts (anemia, leukopenia) Peripheral neuropathy (tingling or numbness) Joint/muscle pain
Metastatic breast cancer Advanced ovarian carcinoma Non-small cell lung cancer (NSCLC) AIDS-related Kaposi’s sarcoma Often used as first-line or second-line therapy, either alone or in combination with other chemotherapeutic agents like cisplatin.
Administered intravenously by trained professionals in a clinical setting. Premedication with corticosteroids, antihistamines, and H2 antagonists is essential to minimize hypersensitivity reactions. Requires close monitoring of blood counts, liver function, and cardiac status.
Store below 25°C, protected from light. Do not freeze. Shake well before use. Keep out of reach of children.
Composition : Abiraterone 250 Mg Tablet
Composition : Acebrophylline (100mg) + Acetylcysteine (600mg)
Composition : Acetylcysteine (600mg) effervescent
Composition : Paclitaxel (100mg) Injection
Composition : Aceclofenac (200mg) + Rabeprazole (20mg) Capsule
Composition : Lactic acid bacillus (100Million spores) + Saccharomyces boulardii (250mg) + Zinc (10mg)
Composition : Glimepiride (1mg) + Metformin (500mg) SR Bilayered Smart Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Palbociclib 125mg Capsule has strong demand in the oncology, breast cancer management, and specialty healthcare segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on oncology and high-value specialty pharmaceutical portfolios.
Medical distributors and agencies can benefit from consistent demand for targeted cancer therapy under specialist medical supervision. Palbociclib 125mg is a Cyclin-Dependent Kinase (CDK) 4/6 inhibitor used as targeted therapy for certain types of breast cancer Commonly prescribed in combination with endocrine therapy for the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as advised by oncologists Helps slow the growth and division of cancer cells by inhibiting CDK 4 and CDK 6, supporting improved disease control The 125mg capsule is the standard starting strength for many treatment regimens, with dose adjustments made according to the patient's tolerance and clinical response Requires strict medical supervision with regular monitoring of complete blood counts, liver function, and treatment response due to the risk of neutropenia and other adverse effects Frequently utilized in oncology centers, breast cancer clinics, tertiary care hospitals, and specialty cancer hospitals Widely prescribed by medical oncologists and breast cancer specialists This strengthens a comprehensive oncology and targeted cancer therapy portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Palbociclib 125mg Capsule with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from consistent specialty prescription demand, high-value oncology market opportunities, institutional procurement, reliable supply chain support, repeat business, and attractive margins in the oncology segment.
Interested distributors, stockists, wholesalers, and institutional suppliers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality oncology products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.